These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 30138325)

  • 1. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
    Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
    PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.
    Deng HY; Wang WP; Wang YC; Hu WP; Ni PZ; Lin YD; Chen LQ
    Eur J Cardiothorac Surg; 2017 Mar; 51(3):421-431. PubMed ID: 27694253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
    von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
    Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.
    Qin Q; Xu H; Liu J; Zhang C; Xu L; Di X; Zhang X; Sun X
    Int J Surg; 2018 Nov; 59():11-18. PubMed ID: 30261331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant chemoradiotherapy combined with operation vs. operation alone for resectable esophageal cancer: Meta-analysis on randomized controlled trials].
    Duan X; Yu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jul; 20(7):809-815. PubMed ID: 28722096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
    Petrelli F; Ghidini M; Barni S; Sgroi G; Passalacqua R; Tomasello G
    Gastric Cancer; 2019 Mar; 22(2):245-254. PubMed ID: 30483986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials.
    Liu B; Bo Y; Wang K; Liu Y; Tang X; Zhao Y; Zhao E; Yuan L
    Oncotarget; 2017 Mar; 8(12):20410-20417. PubMed ID: 28099899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
    Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
    PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis.
    Zhu Y; Chen J; Sun X; Lou Y; Fang M; Zhou F; Zhang L; Xin Y
    Front Oncol; 2023; 13():1177557. PubMed ID: 37228495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers.
    Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Klevebro F; Lindblad M; Ye W; Lundell L; Nilsson M
    Br J Surg; 2014 Mar; 101(4):321-38. PubMed ID: 24493117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
    BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis.
    Liu T; Ding S; Dang J; Wang H; Chen J; Li G
    Radiat Oncol; 2019 Oct; 14(1):176. PubMed ID: 31619265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
    Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
    Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis.
    Jiang L; Yang KH; Guan QL; Chen Y; Zhao P; Tian JH
    J Clin Gastroenterol; 2015; 49(5):387-94. PubMed ID: 25144898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
    Lin G; Han SY; Xu YP; Mao WM
    Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
    Zhao Q; Li Y; Wang J; Zhang J; Qiao X; Tan B; Tian Y; Shi G; Xu Q; Li R; Liu Y; Yang P
    Am J Med Sci; 2015 Jun; 349(6):472-6. PubMed ID: 25996101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
    Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
    Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
    van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
    Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.